VCP and neoplasm: In the context of hypoxia response, UBXD7’s targeting of HIF-1α for degradation via interactions with the p97 complex and CUL2/VHL E3 ubiquitin ligase complexes open new avenues for targeting hypoxic tumours [22, 40].